BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. J Pediatr Gastroenterol Nutr 2017;64:413-7. [PMID: 28230607 DOI: 10.1097/MPG.0000000000001422] [Cited by in Crossref: 89] [Cited by in F6Publishing: 44] [Article Influence: 29.7] [Reference Citation Analysis]
2 Goto M, Iohara D, Michihara A, Ifuku S, Azuma K, Kadowaki D, Maruyama T, Otagiri M, Hirayama F, Anraku M. Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota. Int J Biol Macromol 2020;164:659-66. [PMID: 32698063 DOI: 10.1016/j.ijbiomac.2020.07.184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
4 Kong CY, Li ZM, Han B, Zhang ZY, Chen HL, Zhang SL, Xu JQ, Mao YQ, Zhao YP, Wang LS. Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900249. [PMID: 31271251 DOI: 10.1002/mnfr.201900249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
5 Birjandi M, Ayatollahi SM, Pourahmad S, Safarpour AR. Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J 2016;18:e32858. [PMID: 28191344 DOI: 10.5812/ircmj.32858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 20.0] [Reference Citation Analysis]
7 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
8 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, He Y, Chen Y, Yang Q. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018;102:1025-1036. [PMID: 29710519 DOI: 10.1016/j.biopha.2018.03.158] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 13.7] [Reference Citation Analysis]
10 Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(45): 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20.i45.16841] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
11 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1756-1767 [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
12 Townsend SA, Newsome PN. Non-alcoholic fatty liver disease in 2016. Br Med Bull 2016;119:143-56. [PMID: 27543499 DOI: 10.1093/bmb/ldw031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
13 Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial. Int J Prev Med 2016;7:59. [PMID: 27076897 DOI: 10.4103/2008-7802.178533] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
14 Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B, Nobili V, Lorenza P. Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci. 2014;15:684-711. [PMID: 24402126 DOI: 10.3390/ijms15010684] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
15 Elzouki AN. Probiotics and Liver Disease: Where Are We Now and Where Are We Going? J Clin Gastroenterol. 2016;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & amp; New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S188-S190. [PMID: 27741172 DOI: 10.1097/mcg.0000000000000712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Ben MD, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(26): 8341-8350 [PMID: 25024593 DOI: 10.3748/wjg.v20.i26.8341] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
17 李瑜元. 肠道微生态失调与非酒精性脂肪性肝病关系研究进展. 世界华人消化杂志 2015; 23(15): 2355-2362 [DOI: 10.11569/wcjd.v23.i15.2355] [Reference Citation Analysis]
18 Heebøll S, Thomsen KL, Pedersen SB, Vilstrup H, George J, Grønbæk H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol 2014; 6(4): 188-198 [PMID: 24799987 DOI: 10.4254/wjh.v6.i4.188] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
19 Vajro P, Mandato C, D'Aniello R. More on current evidences on probiotics as a novel treatment for non-alcoholic Fatty liver disease. Hepat Mon 2013;13:e13780. [PMID: 24130602 DOI: 10.5812/hepatmon.13780] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Duncan M, Zong W, Biank VF, Hageman JR. Nonalcoholic Fatty Liver Disease in Pediatrics. Pediatr Ann 2016;45:e54-8. [PMID: 26878184 DOI: 10.3928/00904481-20160113-01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
21 LeBlanc AM, LeBlanc JG. Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J Gastroenterol 2014; 20(44): 16518-16528 [PMID: 25469019 DOI: 10.3748/wjg.v20.i44.16518] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 41] [Article Influence: 8.1] [Reference Citation Analysis]
22 Tsuei J, Chau T, Mills D, Wan YJ. Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer. Exp Biol Med (Maywood) 2014;239:1489-504. [PMID: 24951470 DOI: 10.1177/1535370214538743] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
23 Shi X, Wei X, Yin X, Wang Y, Zhang M, Zhao C, Zhao H, McClain CJ, Feng W, Zhang X. Hepatic and fecal metabolomic analysis of the effects of Lactobacillus rhamnosus GG on alcoholic fatty liver disease in mice. J Proteome Res 2015;14:1174-82. [PMID: 25592873 DOI: 10.1021/pr501121c] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
24 Miccheli A, Capuani G, Marini F, Tomassini A, Praticò G, Ceccarelli S, Gnani D, Baviera G, Alisi A, Putignani L, Nobili V. Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. Int J Obes (Lond) 2015;39:1118-25. [PMID: 25809828 DOI: 10.1038/ijo.2015.40] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
25 Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN 2020;39:53-60. [PMID: 32859329 DOI: 10.1016/j.clnesp.2020.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]